Vassyl Lonchyna to Feasibility Studies
This is a "connection" page, showing publications Vassyl Lonchyna has written about Feasibility Studies.
Connection Strength
0.013
-
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995 Aug; 13(8):1880-92.
Score: 0.007
-
Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg. 1993 Jan; 105(1):97-104; discussion 104-6.
Score: 0.006